Company intelligence / Profile preview

BryoSphere Biotechnologies

Vancouver, British Columbia, Canadabryosphere.ca ↗

Ownership: Private
Development stage: Preclinical

Overview

BryoSphere Biotechnologies has developed a proprietary moss-based biomanufacturing platform to produce sustainable, high-quality bioactive ingredients targeting key skin concerns. The company remains at the seed/R&D stage with no reported clinical trial results or commercialized products as of May 2025.

Therapeutic areas: OtherDermatology
Modalities: Bioactive plant-derived compoundsspecialty chemicals from engineered moss
Industry: Non-Drug Biotech

Drug pipeline

1 asset

BryoBright

Pre-clinical

Indications: Hyperpigmentation

Beyond the preview

Go deeper on BryoSphere Biotechnologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BryoSphere Biotechnologies.

Explore the full profile